Pharmacokinetics of teneligliptin in subjects with renal impairment

Clinical Pharmacology in Drug Development

Volumn 2, Issue 3, 2013, Pages 246-254

  Halabi, Atef ^a   Maatouk, Haidar ^a   Siegler, Karl Ernst ^b   Faisst, Nadja ^b   Lufft, Volkmar ^c   Klause, Norbert ^c  

^a CRS Clinical Research Services Kiel GmbH   (Germany)

^b CRS Clinical Research Services Mannheim GmbH   (Germany)

^c Nephrologisches Zentrum Offenburg   (Germany)

Author keywords

DPP IV inhibitor; End stage renal disease; MP 513; Pharmacokinetics; Renal impairment; Teneligliptin

Indexed keywords

CREATININE; TENELIGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 84891993114     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.29     Document Type: Article

References (15)

1. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997; 20:1822-1826.
2. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29:46-52.
3. Harvey JN. Trends in the prevalence of diabetic neuropathy in type 1 and type 2 diabetes. Curr Opin Nephron Hypertens. 2003; 12(3):317-322.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2011; 34(Suppl 1):S11-S61.
5. Scheen AJ. Pharmackinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12:648-658.
6. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78:675-688.
7. 14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009; 37:536-544.
8. Dhillon S, Weber J. Saxagliptin. Drugs. 2009; 69:2103-2114.
9. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Food and Drug Administration. May 1998.
10. Note for Guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. CPMP/EWP/225/02. London: European Medicines Agency; 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf Accessed on November 29, 2012.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-470.
13. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patientswith type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008; 10:545-555.
14. Thuren T, Byiers S, Mohideen P, Goodman M. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment (Abstract OP 74). Diabetologia. 2008; 51(Suppl 1):S36.
15. Boulton D, Tang A, Patel C, et al. Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Endocr Abstr. 2009; 20:P357.